Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
TECH Stock Chart & Stats
$65.86
-$0.13(-0.17%)
At close: 4:00 PM EST
$65.86
-$0.13(-0.17%)
Day’s Range― - ―
52-Week Range$46.01 - $75.69
Previous CloseN/A
Volume102.39K
Average Volume (3M)2.09M
Market Cap
$10.70B
Enterprise Value$10.61B
Total Cash (Recent Filing)$172.88M
Total Debt (Recent Filing)$337.19M
Price to Earnings (P/E)133.6
Beta0.96
Next Earnings
May 06, 2026EPS Estimate
0.54Next Dividend Ex-DateN/A
Dividend Yield0.54%
Share Statistics
EPS (TTM)0.46
Shares Outstanding155,812,700
10 Day Avg. Volume2,773,999
30 Day Avg. Volume2,085,647
Financial Highlights & Ratios
PEG Ratio-1.97
Price to Book (P/B)4.22
Price to Sales (P/S)6.64
P/FCF Ratio31.59
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue8.73
Enterprise Value/Gross Profit13.39
Enterprise Value/Ebitda61.32
Forecast
1Y Price Target
$73.11Price Target Upside11.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.98
Revenue Forecast (FY)$1.22B
Bulls Say, Bears Say
Bulls Say
Earnings BeatReported quarterly results exceeded revenue and earnings expectations, reinforcing analyst views about the company's underlying business strength.
End-market RecoverySigns of improving demand among large pharmaceutical customers and stabilization in academic and government spending support a pickup in sales as core end markets recover.
Margin Improvement InitiativesMargin expansion from the Exosome divestiture and productivity measures provides a clearer path to profit recovery even with modest organic growth.
Bears Say
Concentration RiskAbove-average exposure to pressured academic and emerging biotech markets increases sensitivity to those cycles and could amplify revenue volatility.
Gross Margin PressureAn unfavorable product mix produced weaker-than-expected gross margins, creating uncertainty about margin sustainability if the mix does not improve.
Order Timing And Guidance RiskTiming of a large OEM reagent order and manufacturing-related headwinds lowered near-term organic growth guidance, indicating potential volatility in reported growth.
Bio-Techne News
TECH FAQ
What was Bio-Techne’s price range in the past 12 months?
Bio-Techne lowest stock price was $46.01 and its highest was $75.69 in the past 12 months.
What is Bio-Techne’s market cap?
Bio-Techne’s market cap is $10.70B.
When is Bio-Techne’s upcoming earnings report date?
Bio-Techne’s upcoming earnings report date is May 06, 2026 which is in 88 days.
How were Bio-Techne’s earnings last quarter?
Bio-Techne released its earnings results on Feb 04, 2026. The company reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.434 by $0.026.
Is Bio-Techne overvalued?
According to Wall Street analysts Bio-Techne’s price is currently Undervalued.
Does Bio-Techne pay dividends?
Bio-Techne pays a Quarterly dividend of $0.08 which represents an annual dividend yield of 0.54%. See more information on Bio-Techne dividends here
What is Bio-Techne’s EPS estimate?
Bio-Techne’s EPS estimate is 0.54.
How many shares outstanding does Bio-Techne have?
Bio-Techne has 155,812,700 shares outstanding.
What happened to Bio-Techne’s price movement after its last earnings report?
Bio-Techne reported an EPS of $0.46 in its last earnings report, beating expectations of $0.434. Following the earnings report the stock price went up 6.251%.
Which hedge fund is a major shareholder of Bio-Techne?
Currently, no hedge funds are holding shares in TECH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bio-Techne Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$73.11 (11.01% Upside)
$73.11 (11.01% Upside)
Blogger Sentiment
Bullish
TECH Sentiment 80%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 95%
Bearish news 5%
Bearish news 5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.09%
12-Months-Change
Fundamentals
Return on Equity
3.96%
Trailing 12-Months
Asset Growth
-5.53%
Trailing 12-Months
Company Description
Bio-Techne
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
TECH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced encouraging execution and strategic progress against clear near-term headwinds. Positive drivers include 10% adjusted EPS growth, ~100 bps operating margin expansion, strong instrument bookings (Comet, LEO), product innovation (Ella assays), geographic momentum in China and APAC, Wilson Wolf growth, and solid cash generation and balance-sheet metrics. Offsetting these positives were flat consolidated revenue, material short‑term order timing impacts from two large cell therapy customers (causing steep GMP reagent declines), gross margin compression from unfavorable product/customer mix, and continued weakness in emerging biotech and parts of academia. Management expects the cell therapy timing headwinds to moderate through Q4 and underlying business trends to improve, supporting a constructive medium-term outlook.View all TECH earnings summariesTECH Net revenue Breakdown
71.35% Protein Sciences
28.39% Diagnostics and Genomics
-0.08% Intersegment
0.34% Other revenue
TECH Stock 12 Month Forecast
Average Price Target
$73.11
▲(11.01% Upside)
Technical Analysis
Corcept Therapeutics
―
Halozyme
―
Jazz Pharmaceuticals
―
Rhythm Pharmaceuticals
―
Roivant Sciences
―
Ownership Overview
0.28% Insiders
38.49% Mutual Funds
2.91% Other Institutional Investors
33.75% Public Companies and
Individual Investors